Open Access<p>ARPP-19 Mediates Herceptin Resistance via Regulation of CD44 in Gastric Cancer</p>
Author(s) -
Xiang Gao,
Changwen Lu,
Changyu Chen,
Kang Sun,
Liang Qi-xin,
Jianfeng Shuai,
Xiaoming Wang,
YiJun Xu
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s253841
Subject(s) - cd44 , cancer , medicine , cancer research , in vivo , gene silencing , cancer cell , mtt assay , in vitro , chemistry , biology , gene , biochemistry , microbiology and biotechnology
As the first-line drug for treatment of HER2 -positive metastatic gastric cancer (GC), Herceptin exhibits significant therapeutic efficacy. However, acquired resistance of Herceptin limits the therapeutic benefit of gastric cancer patients, in which the molecular mechanisms remain to be further determined.